These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37364775)

  • 41. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
    Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
    PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.
    Ison MG; Marty FM; Chao N; Moon SH; Zhang Z; Chandak A
    Transpl Infect Dis; 2022 Aug; 24(4):e13866. PubMed ID: 35598293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Unconventional T Cells Influence Clinical Outcome After Allogeneic Hematopoietic Cell Transplantation.
    Siblany L; Stocker N; Ricard L; Brissot E; Duléry R; Banet A; Sestili S; Belhocine R; Van de Wyngaert Z; Bonnin A; Capes A; Ledraa T; Beurier P; Fadel K; Mohty M; Gaugler B; Malard F
    J Clin Immunol; 2024 Jun; 44(6):139. PubMed ID: 38822857
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis.
    Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
    Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevention of acute graft-versus-host disease in adult T-cell leukemia-lymphoma patients who received mogamulizumab before allogeneic hematopoietic cell transplantation.
    Inoue Y; Nishimura N; Murai M; Matsumoto M; Watanabe M; Yamada A; Izaki M; Nosaka K; Matsuoka M
    Int J Hematol; 2022 Mar; 115(3):435-439. PubMed ID: 34705226
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Graft-
    Devillier R; Eikema DJ; Dufour C; Aljurf M; Wu D; Maschan A; Kulagin A; Halkes CJM; Collin M; Snowden J; Renard C; Ganser A; Sykora KW; Gibson BE; Maertens J; Itäla-Remes M; Corti P; Cornelissen J; Bornhäuser M; Araujo MC; Ozdogu H; Risitano A; Socie G; De Latour RP
    Haematologica; 2023 Sep; 108(9):2305-2315. PubMed ID: 36951165
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.
    García-Cadenas I; Redondo S; Esquirol A; Portos JM; Novelli S; Saavedra S; Moreno C; Garrido A; Oñate G; López J; Caballero AC; Miqueleiz S; Arguello-Tomas M; Briones J; Sierra J; Martino R
    Transplant Cell Ther; 2023 Jul; 29(7):473.e1-473.e6. PubMed ID: 37086849
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dynamic Graft-versus-Host Disease-Free, Relapse-Free Survival: Multistate Modeling of the Morbidity and Mortality of Allotransplantation.
    Holtan SG; Zhang L; DeFor TE; Bejanyan N; Arora M; Rashidi A; Lazaryan A; Kotiso F; Blazar BR; Wagner JE; Brunstein CG; MacMillan ML; Weisdorf DJ
    Biol Blood Marrow Transplant; 2019 Sep; 25(9):1884-1889. PubMed ID: 31128328
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia.
    Dholaria B; Labopin M; Sanz J; Ruggeri A; Cornelissen J; Labussière-Wallet H; Blaise D; Forcade E; Chevallier P; Grassi A; Zubarovskaya L; Kuball J; Ceballos P; Ciceri F; Baron F; Savani BN; Nagler A; Mohty M
    J Hematol Oncol; 2021 May; 14(1):76. PubMed ID: 33941226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Increased Infections and Delayed CD4
    Khimani F; Ranspach P; Elmariah H; Kim J; Whiting J; Nishihori T; Locke FL; Perez Perez A; Dean E; Mishra A; Perez L; Lazaryan A; Jain MD; Nieder M; Liu H; Faramand R; Hansen D; Alsina M; Ochoa L; Davila M; Anasetti C; Pidala J; Bejanyan N
    Transplant Cell Ther; 2021 Nov; 27(11):940-948. PubMed ID: 34329754
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD.
    Dignan FL; Potter MN; Ethell ME; Taylor M; Lewis L; Brennan J; McNamara L; Evans SO; Riley U; Davies FE; Dearden CE; Morgan GJ; Shaw BE
    Clin Transplant; 2013; 27(1):E56-63. PubMed ID: 23278853
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Decitabine in combination with donor lymphocyte infusions can induce remissions in relapsed myeloid malignancies with higher leukemic burden after allogeneic hematopoietic cell transplantation.
    Sommer S; Cruijsen M; Claus R; Bertz H; Wäsch R; Marks R; Zeiser R; Bogatyreva L; Blijlevens NMA; May A; Duyster J; Huls G; van der Velden WJFM; Finke J; Lübbert M
    Leuk Res; 2018 Sep; 72():20-26. PubMed ID: 30064039
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation.
    Hill JA; Moon SH; Chandak A; Zhang Z; Boeckh M; Maziarz RT
    Transplant Cell Ther; 2022 Sep; 28(9):619.e1-619.e8. PubMed ID: 35764288
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD.
    Haverkos BM; Abbott D; Hamadani M; Armand P; Flowers ME; Merryman R; Kamdar M; Kanate AS; Saad A; Mehta A; Ganguly S; Fenske TS; Hari P; Lowsky R; Andritsos L; Jagasia M; Bashey A; Brown S; Bachanova V; Stephens D; Mineishi S; Nakamura R; Chen YB; Blazar BR; Gutman J; Devine SM
    Blood; 2017 Jul; 130(2):221-228. PubMed ID: 28468799
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
    Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase II study of post-transplant cyclophosphamide combined with tacrolimus for GVHD prophylaxis after HLA-matched related/unrelated allogeneic hematopoietic stem cell transplantation.
    Nakamae H; Nakane T; Okamura H; Koh H; Nakashima Y; Hirose A; Nakamae M; Nishimoto M; Kuno M; Makuuchi Y; Harada N; Takakuwa T; Hino M
    Int J Hematol; 2022 Jan; 115(1):77-86. PubMed ID: 34586587
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
    Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
    PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The role of the intestinal microbiota in allogeneic HCT: clinical associations and preclinical mechanisms.
    Nguyen CL; Docampo MD; van den Brink MR; Markey KA
    Curr Opin Genet Dev; 2021 Feb; 66():25-35. PubMed ID: 33388483
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic factors of second hematopoietic allogeneic stem cell transplantation among hematological malignancy patients relapsed after first hematopoietic stem cell transplantation: A single center study.
    Lu Y; Zhang JP; Zhao YL; Xiong M; Sun RJ; Cao XY; Wei ZJ; Zhou JR; Liu DY; Yang JF; Zhang X; Lu DP; Lu P
    Front Immunol; 2022; 13():1066748. PubMed ID: 36685540
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
    Gjærde LK; Ostrowski SR; Jørgensen NR; Schierbeck F; Andersen NS; Friis LS; Kornblit B; Petersen SL; Schjødt I; Sengeløv H
    Transpl Immunol; 2022 Oct; 74():101650. PubMed ID: 35718288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.